Skip to main content

FDA rejects Lilly’s alzheimer’s drug candidate, seeks more data

Lilly said it would work with the FDA to evaluate the fastest pathway to get its Alzheimer’s drug to market after what it believes was a successful trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.